The test, first approved in 2015, helps clinicians predict blood compatibility between donors and patients.
Typically, blood banks use solubility testing to screen for the sickle cell trait. Immucor’s new molecular approach to identifying the trait aims to increase efficiency and limit the rate of false positives, according to the report.
More articles on supply chain:
Medical device execs call for quicker coverage decisions from CMS
States ranked by 2015 generic drug savings
4 latest FDA approvals
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.